Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study

Sleep. 2004 Jun 15;27(4):733-6. doi: 10.1093/sleep/27.4.733.

Abstract

Study objectives: To evaluate an association between catechol-O-methyltransferase (COMT) genotype and subjective daytime sleepiness in patients with Parkinson disease.

Design: Structured questionnaire study.

Setting: Tertiary Parkinson disease care center and sleep outpatients' department at the university hospital neurology department.

Participants: All nondemented patients with idiopathic Parkinson disease who had been part of a previous study of D4-receptor polymorphisms in 1997 were eligible to participate. From the original sample of 113 patients, 46 participated in the study, 22 met exclusion criteria, and 43 were not available.

Interventions: Not applicable.

Measurements and results: In this study, 46 patients were included (27 men, 19 women; 68.4 +/- 9.9 years of age; symptomatic disease duration, 12.2 +/- 5.2 years; Hoehn and Yahr stage in "on" of 2.6 +/- 0.8). Out of the 46 patients, 13 had LL genotype, 22 LH, and 11 HH. The Epworth Sleepiness Scale scores were 9.5 +/- 4.8 in LL, 8.5 +/- 4.7 in LH, and 6.8 +/- 3.1 in HH (mean +/- SD) (NS). LL and LH were grouped together. The Epworth Sleepiness Scale score was 11 or more in 40% of the LL+LH group, compared to 9.1% of the HH group (P = .039). The levodopa or dopamine-agonist doses and types did not differ between the LL+LH group versus the HH group.

Conclusions: These preliminary data suggest an association of the Lallele and daytime sleepiness in patients with Parkinson disease.

MeSH terms

  • Aged
  • Antiparkinson Agents / classification
  • Antiparkinson Agents / therapeutic use*
  • Catechol O-Methyltransferase / genetics*
  • Circadian Rhythm / physiology
  • Disorders of Excessive Somnolence / complications*
  • Disorders of Excessive Somnolence / diagnosis
  • Disorders of Excessive Somnolence / genetics*
  • Female
  • Genotype
  • Humans
  • Male
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy
  • Pilot Projects
  • Polymorphism, Genetic / genetics*
  • Surveys and Questionnaires

Substances

  • Antiparkinson Agents
  • Catechol O-Methyltransferase